Targeting the Nervous System
Neuralstem (NASDAQ:CUR) is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. Our lead stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line in clinical stage testing for treatment of Amyotrophic Lateral Sclerosis (ALS), chronic spinal cord injury (cSCI), and ischemic stroke. Our other clinical-stage product development candidate, NSI-189, is a new chemical entity in clinical development for major depressive disorder (MDD) and in preclinical development for conditions involving cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes, and stroke. These product candidates are based on the company’s proprietary neural stem cell technology.
The company’s technology platform enables the generation and commercial-scale production of regionally specific neural stem cell lines for use in therapeutic indications or drug screening and high content screening of compound libraries for discovery of novel CNS-targeted compounds.
During the spring of 2019 the company announced the initiation of a program to expand its current pipeline of therapeutic products. Neuralstem is focused on the continued development of its current technologies and has also engaged a network of trusted experts and advisors to assist us in evaluating new technologies. This initiative has identified certain preclinical and clinical stage assets that we believe, if developed, could create significant value for shareholders while expanding and diversifying our product pipeline.